“Reputation, built on our past, shapes our present and future. A good reputation can open many doors; a bad reputation can close many more. A good reputation generates respect. A bad reputation breeds suspicion.” Those are not the words of a business consultant or from a television talk show host like Dr. Phil. They are […]
Med Ad News revealed the nominees for the 30th Annual Manny Awards and named Calcium’s Steven Michaelson and Judy Capano as the 2019 Industry Persons of the Year.
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
Pharma continues to lag behind the consumer space in the use of mobile marketing technologies, but the steady advance of consumer tech giants Google and Amazon into the healthcare space means that the industry will have to adapt the tools of AI, voice and chatbots into their marketing, just as their consumer brethren already have.
Intouch Solutions’ Sean Hartigan and Heartbeat’s David Sakadelis say their pharma clients are skittish about the use of chatbots and AI, with an understanding of these technologies more influenced by the grim future of Skynet in the “Terminator” movie franchise rather than the reality of where AI is right now.
In the initial excitement over the possibilities of mobile marketing, pharma rushed to create its own apps. And then these apps languished.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Augmented reality (AR) gained widespread attention the summer of 2016 with the addictive game Pokémon Go. But these days, AR is not just for fun. This disruptive technology is expected to drive significant changes to businesses across many industries because of its ability to combine the virtual and physical worlds.
Augmented reality (AR) and virtual reality (VR) have experienced incredible growth since 2013, when the first Oculus Rift VR headset hit the market and provided a whole new sense of what was possible.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Pharma marketers must listen to their customers and find ways to smooth the patient journey if they are to create effective customer experiences and create loyalty beyond the first prescription.
Consumer/Patient Experience Special Feature: Digital therapeutics – Improving the patient experience at scale
It’s no surprise that the patient experience with the healthcare system often leads to frustration and despair. With chronic disease affecting around 50 percent of the U.S. population, it puts into perspective the sheer volume of patient experiences that are being generated each day and the magnitude of the problems that need solving. The high cost of therapies, the long wait to see a physician, the administrative burden of getting a prior authorization…the list goes on. But the day is coming, and in some cases it’s already here, where a patient could have a robust health system right in their pocket.
Consumer/Patient Experience Special Feature: Masters Of The Pharma Universe: 4 Databases Every Digital Marketer Must Know
Nearly two-thirds of U.S. senior business decision-makers rank big data/analytics first among the technologies necessary for enhancing the customer experience. A similar number put “improving data analysis capabilities” at the top of their priorities.
The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
(Reuters) – Fourteen U.S. and Canadian cancer institutes will use International Business Machines Corp’s (IBM.N) Watson computer system to choose therapies based on a tumor’s genetic fingerprints, the company said on Tuesday, the latest step toward bringing personalized cancer treatments to more patients. Oncology is the first specialty where matching therapy to DNA has […]
MOUNTAIN VIEW, CA–(Marketwired – May 05, 2015) – VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2015. “We have sharpened […]
As Hampton Takes Over as Chairman at GlaxoSmithKline (GSK), CEO Witty Needs to Deliver or “Step Aside”
GlaxoSmithKline (GSK) is under scrutiny Tuesday, after more analysts have called for its longstanding chief executive, Sir Andrew Witty, to either step up his performance or resign within the next year, as the company prepares to receive its new chairman later this week. “Mr. Witty is running out of time,” said Stephen Bailey, a fund […]
ARMONK, N.Y. and DALLAS, May 4, 2015 /PRNewswire/ — IBM (NYSE: IBM) today announced it has completed the acquisition of Phytel, a leading provider of integrated population health management software based in Dallas, Texas. Financial terms of the deal were not disclosed. Phytel is a leader in physician-led population health management software that develops and […]
Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis
Antisense Approach for Clotting Disorders Whippany, NJ – WEBWIRE – Monday, May 04, 2015 Bayer HealthCare (Bayer) has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) on ISIS-FXIRx, an antisense investigational drug in clinical development for the prevention of thrombosis. Under the agreement Bayer will further develop and commercialize ISIS-FXIRx in […]
(Reuters) – German drugmaker Bayer secured the rights to an experimental anti-blood-clotting drug in a deal with California-based Isis Pharmaceuticals to bolster its cardiovascular business led by blockbuster pill Xarelto. Bayer plans to evaluate the blood-thinning drug, called ISIS-FXI, in frail patients that cannot be given currently available drugs because they are at high risk […]
(Reuters) – Corbus Pharmaceuticals Holdings Inc’s experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc’s successful treatment, Kalydeco. Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop the drug, Resunab, and expects […]
Costco Wholesale Corp. filed a complaint in March against Johnson & Johnson (JNJ), accusing J&J’s Vision Care Inc. of price fixing related to its contact lenses. The suit was made public on Friday in J&J’s quarterly report to the U.S. Securities and Exchange Commission (SEC). J&J’s 10-Q filing has a laundry list of updates on […]
New Company to Develop Vaccines, Discovered by City of Hope Researchers, to Protect Against CMV Infections in Cancer Patients
DUARTE, Calif.–(BUSINESS WIRE)–City of Hope and Fortress Biotech have reached an agreement to form a new subsidiary company, DiaVax Biosciences, that will develop two novel vaccines against cytomegalovirus infection, a life-threatening illness in people with weakened or underdeveloped immune systems, such as cancer patients and developing fetuses. Enlisting the defensive power of the immune system, […]